Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
After finishing at $1.81 in the prior trading day, Nuvation Bio Inc (NYSE: NUVB) closed at $1.73, down -4.42%. In other words, the price has decreased by -$4.42 from its previous closing price. On the day, 8.92 million shares were traded.
Ratios:
Our goal is to gain a better understanding of NUVB by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.01 and its Current Ratio is at 9.01. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citizens JMP on April 23, 2025, initiated with a Mkt Outperform rating and assigned the stock a target price of $6.
On March 27, 2024, Jefferies Upgraded its rating to Buy which previously was Hold and also upped its target price recommendation from $1.40 to $10.
BTIG Research Upgraded its Neutral to Buy on March 26, 2024, while the target price for the stock was maintained at $5.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 02 ’25 when Liu Dongfang sold 20,000 shares for $2.50 per share. The transaction valued at 50,024 led to the insider holds 12,000 shares of the business.
DONGFANG LIU bought 20,000 shares of NUVB for $45,400 on May 02 ’25. On Apr 07 ’25, another insider, Hung David, who serves as the PRESIDENT AND CEO of the company, bought 300,000 shares for $1.62 each. As a result, the insider paid 487,500 and bolstered with 58,781,054 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 53.71 while its Price-to-Book (P/B) ratio in mrq is 1.40.
Stock Price History:
Over the past 52 weeks, NUVB has reached a high of $3.97, while it has fallen to a 52-week low of $1.54. The 50-Day Moving Average of the stock is -18.75%, while the 200-Day Moving Average is calculated to be -28.01%.
Shares Statistics:
A total of 338.84M shares are outstanding, with a floating share count of 226.75M. Insiders hold about 33.36% of the company’s shares, while institutions hold 48.62% stake in the company.
Earnings Estimates
The current rating of Nuvation Bio Inc (NUVB) reflects the combined expertise of 1.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.16, with high estimates of -$0.16 and low estimates of -$0.16.
Analysts are recommending an EPS of between -$0.59 and -$0.59 for the fiscal current year, implying an average EPS of -$0.59. EPS for the following year is -$0.59, with 2.0 analysts recommending between -$0.59 and -$0.59.
Revenue Estimates
For the next quarter, 6 analysts are estimating revenue of $3.94M. There is a high estimate of $4.7M for the next quarter, whereas the lowest estimate is $3M.
A total of 7 analysts have provided revenue estimates for NUVB’s current fiscal year. The highest revenue estimate was $22M, while the lowest revenue estimate was $8.6M, resulting in an average revenue estimate of $16.17M. In the same quarter a year ago, actual revenue was $7.87MBased on 7 analysts’ estimates, the company’s revenue will be $80.6M in the next fiscal year. The high estimate is $161.58M and the low estimate is $25M.
